<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215188</url>
  </required_header>
  <id_info>
    <org_study_id>V114-003</org_study_id>
    <secondary_id>V114-003</secondary_id>
    <nct_id>NCT01215188</nct_id>
  </id_info>
  <brief_title>A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)</brief_title>
  <official_title>A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13™ in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether the aluminum-adjuvanted or the non-adjuvanted formulation of
      the candidate pneumococcal vaccine (V114) is non-inferior to Prevnar 13® based on immune
      responses to the 13 serotypes in common Prevnar 13®
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2010</start_date>
  <completion_date type="Actual">July 31, 2012</completion_date>
  <primary_completion_date type="Actual">July 31, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving the Immunoglobulin G (IgG) Serotype-specific ≥0.35 μg/mLThreshold Value for Postvaccination 3</measure>
    <time_frame>One month postvaccination 3</time_frame>
    <description>Percentage of participants meeting the serotype-specific IgG reference level (an antibody concentration measured by the pneumococcal polysaccharide electrochemiluminescence [Pn ECL] assay corresponding to the World Health Organization enzyme-linked immunosorbent assay [WHO ELISA] ≥ 0.35 μg/mL) (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IgG Geometric Mean Concentrations (GMCs) for Postvaccination 3</measure>
    <time_frame>One month postvaccination 3</time_frame>
    <description>The IgG GMCs were evaluated as measured in the Pn ECL assay, for recipients of adjuvanted V114, non-adjuvanted V114, and Prevnar 13® (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IgG GMCs for Postvaccination 4</measure>
    <time_frame>One month postvaccination 4</time_frame>
    <description>The IgG GMCs were evaluated as measured in the Pn ECL assay, for recipients of adjuvanted V114, non-adjuvanted V114, and Prevnar 13® (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Adverse Event (AE)</measure>
    <time_frame>Up to Day 14 postvaccination</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Injection-site AE</measure>
    <time_frame>Up to Day 14 postvaccination</time_frame>
    <description>Injection-site AEs reported by &gt; 0% of participants in one or more vaccination groups were assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Systemic AE</measure>
    <time_frame>Up to Day 14 postvaccination</time_frame>
    <description>Systemic AEs reported by &gt; 0% of participants in one or more vaccination groups were assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Serious Adverse Event (SAE)</measure>
    <time_frame>Up to one month after last dose of study vaccine</time_frame>
    <description>An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued the Study Due to an AE</measure>
    <time_frame>Up to Day 14 postvaccination</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Opsonophagocytic Killing Activity (OPA) Titer ≥ 8 as Measured by Fourfold Multiplexed Opsonization Assay (MOPA4) for Postvaccination 3</measure>
    <time_frame>One month postvaccination 3</time_frame>
    <description>The antibody responses as measured by MOPA4 (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With OPA Titer ≥ 8 as Measured by MOPA4 for Postvaccination 4</measure>
    <time_frame>One month postvaccination 4</time_frame>
    <description>The antibody responses as measured by MOPA4 (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OPA Geometric Mean Titers (GMTs) as Measured by MOPA4 for Postvaccination 3</measure>
    <time_frame>One month postvaccination 3</time_frame>
    <description>The antibody responses as measured by MOPA4 (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. The OPA antibody responses included the percentage of participants with OPA titer and the GMTs. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OPA GMTs as Measured by MOPA4 for Postvaccination 4</measure>
    <time_frame>One month postvaccination 4</time_frame>
    <description>The antibody responses as measured by MOPA4 (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the IgG Serotype-specific Threshold Value of ≥0.35 μg/mL for Postvaccination 4</measure>
    <time_frame>One month postvaccination 4</time_frame>
    <description>Percentage of participants achieving World Health Organization (WHO) predefined antibody threshold as measured by the pneumococcal polysaccharide electrochemiluminescence (Pn ECL) assay corresponding to the WHO enzyme-linked immunosorbent assay (ELISA) value of ≥ 0.35μg/mL (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the IgG Serotype-specific Threshold Value of ≥1.0 μg/mL for Postvaccination 4</measure>
    <time_frame>One month postvaccination 4</time_frame>
    <description>Percentage of participants achieving WHO predefined antibody threshold as measured by the Pn ECL assay corresponding to the WHO enzyme-linked immunosorbent assay (ELISA) value of ≥ 1.0 μg/mL (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1152</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114 Aluminum-adjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V114 Non-adjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four IM doses at 0.5 mL of Prevnar 13® at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 Aluminum-adjuvanted</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.</description>
    <arm_group_label>V114 Aluminum-adjuvanted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 Non-adjuvanted</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.</description>
    <arm_group_label>V114 Non-adjuvanted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13®</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.</description>
    <arm_group_label>Prevnar 13®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy infants ≥ 42 days to ≤ 89 days.

          -  Participant's parent/legal guardian understands the study procedures, alternate
             treatments available and risks involved with the study, and voluntarily agrees to
             allow the child to participate by giving written informed consent.

          -  Afebrile, with a rectal temperature &lt;38.1°C (&lt;100.5°F) or axillary temperature &lt;37.8°C
             (&lt;100.0°F) on day of vaccination.

          -  Participant's parent/legal guardian is able to read, understand, and complete study
             questionnaires (i.e., the Vaccination Report Card).

          -  Participant is able to attend all scheduled visits and to comply with the study
             procedures.

          -  Participant's parent/legal guardian has access to a telephone.

        Exclusion Criteria:

          -  Prior administration of any pneumococcal vaccine.

          -  Known hypersensitivity to any component of the pneumococcal conjugate vaccine.

          -  Known or suspected impairment of immunological function.

          -  Participant has a history of congenital or acquired immunodeficiency (e.g.,
             splenomegaly).

          -  Participant or his/her mother has documented human immunodeficiency virus (HIV)
             infection.

          -  Functional or anatomic asplenia.

          -  History of autoimmune disease including multiple sclerosis (MS), systemic lupus,
             polymyositis, inclusion body myositis, dermatomyositis, Hashimoto's thyroiditis,
             Sjogren's syndrome, rheumatoid arthritis, other autoimmune disorders.

          -  Known neurologic or cognitive behavioral disorders including multiple sclerosis (MS),
             MS-like disease, encephalitis/myelitis, acute disseminating encephalomyelitis,
             pervasive developmental disorder, and related disorders.

          -  Use of any immunosuppressive therapy (Note: topical and inhaled/nebulized steroids are
             permitted). Participants on intramuscular, oral, or intravenous corticosteroid
             treatment should be excluded if they are receiving or expected to receive in the
             period from 30 days prior to Visit 1 through Visit 6 (30 days post-dose 4) more than 2
             mg/kg per day of prednisone (or its equivalent), or more than 20 mg/d if they weigh
             more than 10 kg and are not otherwise immunocompromised. Excluded immunosuppressive
             therapies also include chemotherapeutic agents used to treat cancer or other
             conditions, and treatments associated with organ or bone marrow transplantation, or
             autoimmune disease.

          -  Participant has received other licensed non-live vaccines within the 14 days before
             receipt of study vaccine.

          -  Participant has received a licensed live virus vaccine within the 30 days prior of
             receipt of study vaccine.

          -  Prior receipt of a blood transfusion or blood products, including immunoglobulins.

          -  Investigational drugs or vaccines received within the 2 months before receipt of study
             vaccine.

          -  Participation in another clinical study within 42 days before the beginning or anytime
             during the duration of the current clinical study.

          -  History of invasive pneumococcal disease (positive blood culture, positive
             cerebrospinal fluid culture, or other sterile site) or known history of other culture
             positive pneumococcal disease.

          -  A recent febrile illness (rectal temperature ≥38.1°C [≥100.5°F]) occurring within 72
             hours before receipt of study vaccine.

          -  History of failure to thrive.

          -  Participant has a coagulation disorder contraindicating IM vaccination.

          -  Participant and his/her mother have documented hepatitis B surface antigen-positive.

          -  Any infant who cannot be adequately followed for safety according to the protocol
             plan.

          -  Participant's parent/legal guardian is unlikely to adhere to study procedures, keep
             appointments, or is planning to relocate during the study.

          -  Any other reason that in the opinion of the investigator may interfere with the
             evaluation required by the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <results_first_submitted>April 8, 2019</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Invasive pneumococcal disease</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted in 58 trial centers: 4 in Canada, 8 in Finland, 3 in Israel, 1 in Puerto Rico, 3 in Spain and 39 in the United States.</recruitment_details>
      <pre_assignment_details>There were 1152 participants randomized into the study. The 1142 participants included in this study excluded 4 subjects who each received a combination of vaccines and who each had a final disposition of completed and excludes an additional 6 subjects who were randomized but never vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>V114 Adjuvanted</title>
          <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
        <group group_id="P2">
          <title>V114 Nonadjuvanted</title>
          <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
        <group group_id="P3">
          <title>PREVNAR 13®</title>
          <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="378"/>
                <participants group_id="P2" count="386"/>
                <participants group_id="P3" count="378"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="320"/>
                <participants group_id="P2" count="327"/>
                <participants group_id="P3" count="326"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V114 Adjuvanted</title>
          <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
        <group group_id="B2">
          <title>V114 Nonadjuvanted</title>
          <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
        <group group_id="B3">
          <title>PREVNAR 13®</title>
          <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="378"/>
            <count group_id="B2" value="386"/>
            <count group_id="B3" value="378"/>
            <count group_id="B4" value="1142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="1.2"/>
                    <measurement group_id="B2" value="8.8" spread="1.2"/>
                    <measurement group_id="B3" value="8.7" spread="1.1"/>
                    <measurement group_id="B4" value="8.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="545"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="199"/>
                    <measurement group_id="B4" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="226"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="299"/>
                    <measurement group_id="B4" value="916"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="831"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving the Immunoglobulin G (IgG) Serotype-specific ≥0.35 μg/mLThreshold Value for Postvaccination 3</title>
        <description>Percentage of participants meeting the serotype-specific IgG reference level (an antibody concentration measured by the pneumococcal polysaccharide electrochemiluminescence [Pn ECL] assay corresponding to the World Health Organization enzyme-linked immunosorbent assay [WHO ELISA] ≥ 0.35 μg/mL) (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
        <time_frame>One month postvaccination 3</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the Immunoglobulin G (IgG) Serotype-specific ≥0.35 μg/mLThreshold Value for Postvaccination 3</title>
          <description>Percentage of participants meeting the serotype-specific IgG reference level (an antibody concentration measured by the pneumococcal polysaccharide electrochemiluminescence [Pn ECL] assay corresponding to the World Health Organization enzyme-linked immunosorbent assay [WHO ELISA] ≥ 0.35 μg/mL) (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="95.7" upper_limit="99.3"/>
                    <measurement group_id="O2" value="96.2" lower_limit="93.4" upper_limit="98.0"/>
                    <measurement group_id="O3" value="97.5" lower_limit="95.1" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="89.9" upper_limit="95.9"/>
                    <measurement group_id="O2" value="89.8" lower_limit="86.0" upper_limit="92.9"/>
                    <measurement group_id="O3" value="69.2" lower_limit="63.8" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="94.4" upper_limit="98.6"/>
                    <measurement group_id="O2" value="94.0" lower_limit="90.7" upper_limit="96.3"/>
                    <measurement group_id="O3" value="96.5" lower_limit="93.8" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.7" upper_limit="97.7"/>
                    <measurement group_id="O2" value="92.4" lower_limit="88.9" upper_limit="95.1"/>
                    <measurement group_id="O3" value="96.2" lower_limit="93.4" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" lower_limit="71.8" upper_limit="81.6"/>
                    <measurement group_id="O2" value="78.4" lower_limit="73.5" upper_limit="82.8"/>
                    <measurement group_id="O3" value="96.8" lower_limit="94.2" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="68.3" upper_limit="78.6"/>
                    <measurement group_id="O2" value="65.4" lower_limit="59.9" upper_limit="70.6"/>
                    <measurement group_id="O3" value="87.6" lower_limit="83.5" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="99.4" lower_limit="97.7" upper_limit="100"/>
                    <measurement group_id="O3" value="99.4" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="91.9" upper_limit="97.2"/>
                    <measurement group_id="O2" value="92.4" lower_limit="88.9" upper_limit="95.1"/>
                    <measurement group_id="O3" value="97.5" lower_limit="95.1" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="96.6" upper_limit="100"/>
                    <measurement group_id="O2" value="98.4" lower_limit="96.3" upper_limit="99.5"/>
                    <measurement group_id="O3" value="97.8" lower_limit="95.5" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="94.0" upper_limit="98.4"/>
                    <measurement group_id="O2" value="89.8" lower_limit="86.0" upper_limit="92.9"/>
                    <measurement group_id="O3" value="97.5" lower_limit="95.1" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" lower_limit="77.9" upper_limit="86.8"/>
                    <measurement group_id="O2" value="84.4" lower_limit="80.0" upper_limit="88.3"/>
                    <measurement group_id="O3" value="96.5" lower_limit="93.8" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="87.6" upper_limit="94.3"/>
                    <measurement group_id="O2" value="91.1" lower_limit="87.4" upper_limit="94.0"/>
                    <measurement group_id="O3" value="99.4" lower_limit="97.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O2" value="99.4" lower_limit="97.7" upper_limit="100"/>
                    <measurement group_id="O3" value="1.9" lower_limit="0.7" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="83.4" upper_limit="91.2"/>
                    <measurement group_id="O2" value="81.6" lower_limit="76.9" upper_limit="85.7"/>
                    <measurement group_id="O3" value="90.8" lower_limit="87.0" upper_limit="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="78.6" upper_limit="87.4"/>
                    <measurement group_id="O2" value="84.8" lower_limit="80.3" upper_limit="88.5"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IgG Geometric Mean Concentrations (GMCs) for Postvaccination 3</title>
        <description>The IgG GMCs were evaluated as measured in the Pn ECL assay, for recipients of adjuvanted V114, non-adjuvanted V114, and Prevnar 13® (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
        <time_frame>One month postvaccination 3</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>IgG Geometric Mean Concentrations (GMCs) for Postvaccination 3</title>
          <description>The IgG GMCs were evaluated as measured in the Pn ECL assay, for recipients of adjuvanted V114, non-adjuvanted V114, and Prevnar 13® (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="1.24" upper_limit="1.45"/>
                    <measurement group_id="O2" value="1.38" lower_limit="1.27" upper_limit="1.51"/>
                    <measurement group_id="O3" value="1.84" lower_limit="1.69" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.88" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.81" upper_limit="0.96"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.46" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="1.18" upper_limit="1.39"/>
                    <measurement group_id="O2" value="1.26" lower_limit="1.16" upper_limit="1.37"/>
                    <measurement group_id="O3" value="1.32" lower_limit="1.22" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="1.46" upper_limit="1.77"/>
                    <measurement group_id="O2" value="1.53" lower_limit="1.38" upper_limit="1.71"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.65" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.80" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.80" upper_limit="1.07"/>
                    <measurement group_id="O3" value="2.91" lower_limit="2.62" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.78" upper_limit="1.15"/>
                    <measurement group_id="O2" value="0.69" lower_limit="0.57" upper_limit="0.84"/>
                    <measurement group_id="O3" value="1.47" lower_limit="1.27" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" lower_limit="2.41" upper_limit="2.87"/>
                    <measurement group_id="O2" value="2.66" lower_limit="2.44" upper_limit="2.90"/>
                    <measurement group_id="O3" value="3.67" lower_limit="3.40" upper_limit="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="1.35" upper_limit="1.64"/>
                    <measurement group_id="O2" value="1.29" lower_limit="1.16" upper_limit="1.44"/>
                    <measurement group_id="O3" value="1.79" lower_limit="1.63" upper_limit="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="3.76" upper_limit="4.63"/>
                    <measurement group_id="O2" value="3.84" lower_limit="3.43" upper_limit="4.29"/>
                    <measurement group_id="O3" value="5.62" lower_limit="5.02" upper_limit="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="1.17" upper_limit="1.39"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.97" upper_limit="1.20"/>
                    <measurement group_id="O3" value="1.99" lower_limit="1.81" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.80" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.84" upper_limit="1.05"/>
                    <measurement group_id="O3" value="2.05" lower_limit="1.85" upper_limit="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.33" upper_limit="1.69"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.52" upper_limit="1.93"/>
                    <measurement group_id="O3" value="2.54" lower_limit="2.35" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" lower_limit="4.74" upper_limit="5.79"/>
                    <measurement group_id="O2" value="4.86" lower_limit="4.40" upper_limit="5.37"/>
                    <measurement group_id="O3" value="0.07" lower_limit="0.06" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.94" upper_limit="1.17"/>
                    <measurement group_id="O2" value="0.79" lower_limit="0.69" upper_limit="0.89"/>
                    <measurement group_id="O3" value="1.41" lower_limit="1.25" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="1.24" upper_limit="1.73"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.29" upper_limit="1.74"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.06" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IgG GMCs for Postvaccination 4</title>
        <description>The IgG GMCs were evaluated as measured in the Pn ECL assay, for recipients of adjuvanted V114, non-adjuvanted V114, and Prevnar 13® (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
        <time_frame>One month postvaccination 4</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>IgG GMCs for Postvaccination 4</title>
          <description>The IgG GMCs were evaluated as measured in the Pn ECL assay, for recipients of adjuvanted V114, non-adjuvanted V114, and Prevnar 13® (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="298"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="1.73" upper_limit="2.10"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.65" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.18" lower_limit="1.99" upper_limit="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.15" upper_limit="1.39"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.04" upper_limit="1.22"/>
                    <measurement group_id="O3" value="0.69" lower_limit="0.63" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.30" upper_limit="1.65"/>
                    <measurement group_id="O2" value="1.40" lower_limit="1.27" upper_limit="1.53"/>
                    <measurement group_id="O3" value="1.68" lower_limit="1.52" upper_limit="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" lower_limit="1.74" upper_limit="2.14"/>
                    <measurement group_id="O2" value="1.79" lower_limit="1.63" upper_limit="1.97"/>
                    <measurement group_id="O3" value="2.53" lower_limit="2.28" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="297"/>
                    <count group_id="O3" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" lower_limit="3.37" upper_limit="4.26"/>
                    <measurement group_id="O2" value="3.17" lower_limit="2.81" upper_limit="3.57"/>
                    <measurement group_id="O3" value="6.55" lower_limit="5.89" upper_limit="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" lower_limit="4.68" upper_limit="5.86"/>
                    <measurement group_id="O2" value="3.98" lower_limit="3.52" upper_limit="4.51"/>
                    <measurement group_id="O3" value="5.51" lower_limit="4.90" upper_limit="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" lower_limit="3.76" upper_limit="4.64"/>
                    <measurement group_id="O2" value="3.43" lower_limit="3.14" upper_limit="3.75"/>
                    <measurement group_id="O3" value="5.73" lower_limit="5.24" upper_limit="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" lower_limit="2.52" upper_limit="3.15"/>
                    <measurement group_id="O2" value="2.50" lower_limit="2.28" upper_limit="2.75"/>
                    <measurement group_id="O3" value="3.37" lower_limit="3.04" upper_limit="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" lower_limit="5.37" upper_limit="6.82"/>
                    <measurement group_id="O2" value="5.55" lower_limit="4.99" upper_limit="6.17"/>
                    <measurement group_id="O3" value="7.57" lower_limit="6.81" upper_limit="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="1.94" upper_limit="2.37"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.54" upper_limit="1.83"/>
                    <measurement group_id="O3" value="3.37" lower_limit="3.06" upper_limit="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="2.72" upper_limit="3.40"/>
                    <measurement group_id="O2" value="3.42" lower_limit="3.03" upper_limit="3.87"/>
                    <measurement group_id="O3" value="6.14" lower_limit="5.57" upper_limit="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" lower_limit="4.99" upper_limit="6.20"/>
                    <measurement group_id="O2" value="6.35" lower_limit="5.68" upper_limit="7.09"/>
                    <measurement group_id="O3" value="4.51" lower_limit="4.07" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" lower_limit="8.74" upper_limit="10.62"/>
                    <measurement group_id="O2" value="7.73" lower_limit="7.08" upper_limit="8.45"/>
                    <measurement group_id="O3" value="0.12" lower_limit="0.11" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1.75" upper_limit="2.26"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.43" upper_limit="1.80"/>
                    <measurement group_id="O3" value="3.14" lower_limit="2.78" upper_limit="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" lower_limit="5.62" upper_limit="7.05"/>
                    <measurement group_id="O2" value="4.95" lower_limit="4.46" upper_limit="5.51"/>
                    <measurement group_id="O3" value="0.08" lower_limit="0.08" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Adverse Event (AE)</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
        <time_frame>Up to Day 14 postvaccination</time_frame>
        <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Adverse Event (AE)</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
          <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349"/>
                    <measurement group_id="O2" value="359"/>
                    <measurement group_id="O3" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Injection-site AE</title>
        <description>Injection-site AEs reported by &gt; 0% of participants in one or more vaccination groups were assessed.</description>
        <time_frame>Up to Day 14 postvaccination</time_frame>
        <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Injection-site AE</title>
          <description>Injection-site AEs reported by &gt; 0% of participants in one or more vaccination groups were assessed.</description>
          <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                    <measurement group_id="O2" value="302"/>
                    <measurement group_id="O3" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Systemic AE</title>
        <description>Systemic AEs reported by &gt; 0% of participants in one or more vaccination groups were assessed.</description>
        <time_frame>Up to Day 14 postvaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Systemic AE</title>
          <description>Systemic AEs reported by &gt; 0% of participants in one or more vaccination groups were assessed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="352"/>
                    <measurement group_id="O3" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Serious Adverse Event (SAE)</title>
        <description>An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
        <time_frame>Up to one month after last dose of study vaccine</time_frame>
        <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Serious Adverse Event (SAE)</title>
          <description>An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
          <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued the Study Due to an AE</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
        <time_frame>Up to Day 14 postvaccination</time_frame>
        <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued the Study Due to an AE</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
          <population>The analysis population included all randomized participants who received at least one dose of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Opsonophagocytic Killing Activity (OPA) Titer ≥ 8 as Measured by Fourfold Multiplexed Opsonization Assay (MOPA4) for Postvaccination 3</title>
        <description>The antibody responses as measured by MOPA4 (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
        <time_frame>One month postvaccination 3</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Opsonophagocytic Killing Activity (OPA) Titer ≥ 8 as Measured by Fourfold Multiplexed Opsonization Assay (MOPA4) for Postvaccination 3</title>
          <description>The antibody responses as measured by MOPA4 (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="71.7" upper_limit="86.7"/>
                    <measurement group_id="O2" value="73.3" lower_limit="64.5" upper_limit="81.0"/>
                    <measurement group_id="O3" value="77.7" lower_limit="69.2" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.0" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.0" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="96.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O2" value="95.8" lower_limit="90.5" upper_limit="98.6"/>
                    <measurement group_id="O3" value="97.5" lower_limit="93.0" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" lower_limit="82.2" upper_limit="94.1"/>
                    <measurement group_id="O2" value="85.8" lower_limit="78.3" upper_limit="91.5"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="76.2" upper_limit="90.1"/>
                    <measurement group_id="O2" value="80.0" lower_limit="71.7" upper_limit="86.7"/>
                    <measurement group_id="O3" value="96.7" lower_limit="91.8" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.0" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.0" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.0" upper_limit="100"/>
                    <measurement group_id="O2" value="98.3" lower_limit="94.1" upper_limit="100"/>
                    <measurement group_id="O3" value="99.2" lower_limit="95.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.0" upper_limit="100"/>
                    <measurement group_id="O2" value="99.2" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O2" value="96.7" lower_limit="91.7" upper_limit="99.1"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="86.2" upper_limit="96.5"/>
                    <measurement group_id="O2" value="95.0" lower_limit="89.3" upper_limit="98.1"/>
                    <measurement group_id="O3" value="95.9" lower_limit="90.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="89.4" upper_limit="98.1"/>
                    <measurement group_id="O2" value="95.8" lower_limit="90.5" upper_limit="98.6"/>
                    <measurement group_id="O3" value="99.2" lower_limit="95.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.0" upper_limit="100"/>
                    <measurement group_id="O3" value="11.6" lower_limit="6.5" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="92.9" upper_limit="99.5"/>
                    <measurement group_id="O2" value="96.6" lower_limit="91.6" upper_limit="99.1"/>
                    <measurement group_id="O3" value="96.7" lower_limit="91.8" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="92.9" upper_limit="99.5"/>
                    <measurement group_id="O2" value="99.2" lower_limit="95.4" upper_limit="100"/>
                    <measurement group_id="O3" value="60.7" lower_limit="51.4" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With OPA Titer ≥ 8 as Measured by MOPA4 for Postvaccination 4</title>
        <description>The antibody responses as measured by MOPA4 (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
        <time_frame>One month postvaccination 4</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With OPA Titer ≥ 8 as Measured by MOPA4 for Postvaccination 4</title>
          <description>The antibody responses as measured by MOPA4 (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="88.1" upper_limit="100"/>
                    <measurement group_id="O2" value="94.9" lower_limit="85.9" upper_limit="98.9"/>
                    <measurement group_id="O3" value="96.0" lower_limit="86.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O2" value="98.3" lower_limit="90.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="88.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O3" value="17.0" lower_limit="7.6" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="92.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100.0" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O3" value="88.0" lower_limit="75.7" upper_limit="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OPA Geometric Mean Titers (GMTs) as Measured by MOPA4 for Postvaccination 3</title>
        <description>The antibody responses as measured by MOPA4 (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. The OPA antibody responses included the percentage of participants with OPA titer and the GMTs. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
        <time_frame>One month postvaccination 3</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>OPA Geometric Mean Titers (GMTs) as Measured by MOPA4 for Postvaccination 3</title>
          <description>The antibody responses as measured by MOPA4 (post-dose 3) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. The OPA antibody responses included the percentage of participants with OPA titer and the GMTs. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" lower_limit="25.4" upper_limit="49.3"/>
                    <measurement group_id="O2" value="32.4" lower_limit="22.5" upper_limit="46.5"/>
                    <measurement group_id="O3" value="44.6" lower_limit="31.2" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.7" lower_limit="246.9" upper_limit="356.6"/>
                    <measurement group_id="O2" value="254.3" lower_limit="215.9" upper_limit="299.6"/>
                    <measurement group_id="O3" value="209.9" lower_limit="178.6" upper_limit="246.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1672.9" lower_limit="1414.3" upper_limit="1978.7"/>
                    <measurement group_id="O2" value="1633.1" lower_limit="1384.3" upper_limit="1926.6"/>
                    <measurement group_id="O3" value="1911.6" lower_limit="1608.0" upper_limit="2272.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467.6" lower_limit="369.4" upper_limit="591.7"/>
                    <measurement group_id="O2" value="337.0" lower_limit="259.5" upper_limit="437.7"/>
                    <measurement group_id="O3" value="542.8" lower_limit="416.8" upper_limit="706.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1273.6" lower_limit="807.3" upper_limit="2009.1"/>
                    <measurement group_id="O2" value="703.3" lower_limit="435.4" upper_limit="1136.1"/>
                    <measurement group_id="O3" value="4009.7" lower_limit="3316.0" upper_limit="4848.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="765.5" lower_limit="463.2" upper_limit="1265.2"/>
                    <measurement group_id="O2" value="419.5" lower_limit="244.8" upper_limit="719.0"/>
                    <measurement group_id="O3" value="1597.5" lower_limit="1145.7" upper_limit="2227.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5818.1" lower_limit="4945.3" upper_limit="6844.8"/>
                    <measurement group_id="O2" value="5791.3" lower_limit="4816.9" upper_limit="6962.9"/>
                    <measurement group_id="O3" value="10454.1" lower_limit="8614.1" upper_limit="12687.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2227.4" lower_limit="1791.0" upper_limit="2770.1"/>
                    <measurement group_id="O2" value="1927.3" lower_limit="1493.8" upper_limit="2486.5"/>
                    <measurement group_id="O3" value="2685.5" lower_limit="2110.5" upper_limit="3417.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2266.2" lower_limit="1835.9" upper_limit="2797.2"/>
                    <measurement group_id="O2" value="1574.8" lower_limit="1232.4" upper_limit="2012.3"/>
                    <measurement group_id="O3" value="2786.5" lower_limit="2244.3" upper_limit="3459.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1263.7" lower_limit="1035.4" upper_limit="1542.2"/>
                    <measurement group_id="O2" value="846.6" lower_limit="652.4" upper_limit="1098.8"/>
                    <measurement group_id="O3" value="2209.0" lower_limit="1833.1" upper_limit="2662.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="551.7" lower_limit="383.3" upper_limit="794.1"/>
                    <measurement group_id="O2" value="457.9" lower_limit="331.1" upper_limit="633.3"/>
                    <measurement group_id="O3" value="1292.1" lower_limit="921.9" upper_limit="1810.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="986.2" lower_limit="714.0" upper_limit="1362.2"/>
                    <measurement group_id="O2" value="933.7" lower_limit="665.8" upper_limit="1309.5"/>
                    <measurement group_id="O3" value="1417.1" lower_limit="1145.4" upper_limit="1753.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3048.8" lower_limit="2484.3" upper_limit="3741.5"/>
                    <measurement group_id="O2" value="2714.4" lower_limit="2302.6" upper_limit="3199.9"/>
                    <measurement group_id="O3" value="3.9" lower_limit="2.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="119"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1087.7" lower_limit="821.8" upper_limit="1439.8"/>
                    <measurement group_id="O2" value="726.4" lower_limit="530.3" upper_limit="995.1"/>
                    <measurement group_id="O3" value="3040.3" lower_limit="2249.0" upper_limit="4110.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25075.2" lower_limit="16645.2" upper_limit="37774.5"/>
                    <measurement group_id="O2" value="28262.3" lower_limit="20745.0" upper_limit="38503.5"/>
                    <measurement group_id="O3" value="66.6" lower_limit="39.0" upper_limit="113.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OPA GMTs as Measured by MOPA4 for Postvaccination 4</title>
        <description>The antibody responses as measured by MOPA4 (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
        <time_frame>One month postvaccination 4</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>OPA GMTs as Measured by MOPA4 for Postvaccination 4</title>
          <description>The antibody responses as measured by MOPA4 (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®. Functional antibody activity was assessed only in a subset of the vaccinated participants, thus the study was not powered for assessing non-inferiority with respect to the OPA antibody responses.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.1" lower_limit="90.0" upper_limit="215.0"/>
                    <measurement group_id="O2" value="124.0" lower_limit="79.6" upper_limit="192.9"/>
                    <measurement group_id="O3" value="133.1" lower_limit="86.3" upper_limit="205.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.6" lower_limit="344.8" upper_limit="557.9"/>
                    <measurement group_id="O2" value="405.2" lower_limit="330.0" upper_limit="497.4"/>
                    <measurement group_id="O3" value="369.7" lower_limit="293.8" upper_limit="465.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1674.3" lower_limit="1171.5" upper_limit="2392.9"/>
                    <measurement group_id="O2" value="1752.9" lower_limit="1394.0" upper_limit="2204.0"/>
                    <measurement group_id="O3" value="2456.5" lower_limit="1895.1" upper_limit="3184.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.8" lower_limit="474.7" upper_limit="976.6"/>
                    <measurement group_id="O2" value="866.5" lower_limit="648.5" upper_limit="1157.9"/>
                    <measurement group_id="O3" value="830.3" lower_limit="602.1" upper_limit="1144.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2583.6" lower_limit="1667.0" upper_limit="4004.2"/>
                    <measurement group_id="O2" value="2835.9" lower_limit="2171.6" upper_limit="3703.5"/>
                    <measurement group_id="O3" value="7382.0" lower_limit="5445.2" upper_limit="10007.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3866.8" lower_limit="2723.7" upper_limit="5489.7"/>
                    <measurement group_id="O2" value="2265.1" lower_limit="1559.4" upper_limit="3290.2"/>
                    <measurement group_id="O3" value="4686.1" lower_limit="3058.7" upper_limit="7179.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10205.9" lower_limit="7487.6" upper_limit="13911.2"/>
                    <measurement group_id="O2" value="8543.2" lower_limit="6622.6" upper_limit="11020.6"/>
                    <measurement group_id="O3" value="19147.5" lower_limit="13725.9" upper_limit="26710.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2888.0" lower_limit="1985.0" upper_limit="4201.7"/>
                    <measurement group_id="O2" value="3339.1" lower_limit="2457.9" upper_limit="4536.2"/>
                    <measurement group_id="O3" value="4901.5" lower_limit="3740.3" upper_limit="6423.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3543.1" lower_limit="2508.3" upper_limit="5005.0"/>
                    <measurement group_id="O2" value="2877.7" lower_limit="2088.7" upper_limit="3964.7"/>
                    <measurement group_id="O3" value="3872.9" lower_limit="2762.1" upper_limit="5430.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1327.0" lower_limit="945.3" upper_limit="1862.8"/>
                    <measurement group_id="O2" value="1171.1" lower_limit="928.6" upper_limit="1476.9"/>
                    <measurement group_id="O3" value="3214.7" lower_limit="2438.0" upper_limit="4238.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1871.0" lower_limit="1282.1" upper_limit="2730.4"/>
                    <measurement group_id="O2" value="2260.8" lower_limit="1604.8" upper_limit="3185.0"/>
                    <measurement group_id="O3" value="4519.7" lower_limit="3028.7" upper_limit="6744.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1885.8" lower_limit="1226.6" upper_limit="2899.2"/>
                    <measurement group_id="O2" value="2949.8" lower_limit="2273.6" upper_limit="3827.0"/>
                    <measurement group_id="O3" value="2624.6" lower_limit="1866.0" upper_limit="3691.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4586.5" lower_limit="3406.2" upper_limit="6175.7"/>
                    <measurement group_id="O2" value="4497.0" lower_limit="3594.5" upper_limit="5626.1"/>
                    <measurement group_id="O3" value="4.8" lower_limit="2.6" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3118.0" lower_limit="2203.2" upper_limit="4412.6"/>
                    <measurement group_id="O2" value="2469.2" lower_limit="1904.5" upper_limit="3201.4"/>
                    <measurement group_id="O3" value="11490.0" lower_limit="7815.4" upper_limit="16892.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59179.6" lower_limit="43706.0" upper_limit="80131.4"/>
                    <measurement group_id="O2" value="54562.2" lower_limit="38760.3" upper_limit="76806.2"/>
                    <measurement group_id="O3" value="815.8" lower_limit="408.0" upper_limit="1631.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the IgG Serotype-specific Threshold Value of ≥0.35 μg/mL for Postvaccination 4</title>
        <description>Percentage of participants achieving World Health Organization (WHO) predefined antibody threshold as measured by the pneumococcal polysaccharide electrochemiluminescence (Pn ECL) assay corresponding to the WHO enzyme-linked immunosorbent assay (ELISA) value of ≥ 0.35μg/mL (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
        <time_frame>One month postvaccination 4</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the IgG Serotype-specific Threshold Value of ≥0.35 μg/mL for Postvaccination 4</title>
          <description>Percentage of participants achieving World Health Organization (WHO) predefined antibody threshold as measured by the pneumococcal polysaccharide electrochemiluminescence (Pn ECL) assay corresponding to the WHO enzyme-linked immunosorbent assay (ELISA) value of ≥ 0.35μg/mL (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="95.8" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98.0" lower_limit="95.7" upper_limit="99.3"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="92.9" upper_limit="98.0"/>
                    <measurement group_id="O2" value="95.9" lower_limit="93.0" upper_limit="97.9"/>
                    <measurement group_id="O3" value="80.9" lower_limit="75.8" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="92.5" upper_limit="97.7"/>
                    <measurement group_id="O2" value="96.3" lower_limit="93.5" upper_limit="98.1"/>
                    <measurement group_id="O3" value="96.8" lower_limit="94.0" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.4" upper_limit="100"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O3" value="98.9" lower_limit="96.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="297"/>
                    <count group_id="O3" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.3" upper_limit="100"/>
                    <measurement group_id="O2" value="97.3" lower_limit="94.8" upper_limit="98.8"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.4" upper_limit="100"/>
                    <measurement group_id="O2" value="97.7" lower_limit="95.2" upper_limit="99.1"/>
                    <measurement group_id="O3" value="98.9" lower_limit="96.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.8" upper_limit="100"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O3" value="99.6" lower_limit="98.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.1" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.3" upper_limit="100"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="94.8" upper_limit="99.0"/>
                    <measurement group_id="O2" value="98.7" lower_limit="96.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.4" upper_limit="100"/>
                    <measurement group_id="O2" value="99.0" lower_limit="97.1" upper_limit="100"/>
                    <measurement group_id="O3" value="99.3" lower_limit="97.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.1" upper_limit="100"/>
                    <measurement group_id="O3" value="7.4" lower_limit="4.7" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="92.5" upper_limit="97.7"/>
                    <measurement group_id="O2" value="95.0" lower_limit="91.8" upper_limit="97.2"/>
                    <measurement group_id="O3" value="98.9" lower_limit="96.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.8" upper_limit="100"/>
                    <measurement group_id="O2" value="98.3" lower_limit="96.1" upper_limit="99.5"/>
                    <measurement group_id="O3" value="4.9" lower_limit="2.7" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the IgG Serotype-specific Threshold Value of ≥1.0 μg/mL for Postvaccination 4</title>
        <description>Percentage of participants achieving WHO predefined antibody threshold as measured by the Pn ECL assay corresponding to the WHO enzyme-linked immunosorbent assay (ELISA) value of ≥ 1.0 μg/mL (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
        <time_frame>One month postvaccination 4</time_frame>
        <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
        <group_list>
          <group group_id="O1">
            <title>V114 Adjuvanted</title>
            <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>V114 Nonadjuvanted</title>
            <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the IgG Serotype-specific Threshold Value of ≥1.0 μg/mL for Postvaccination 4</title>
          <description>Percentage of participants achieving WHO predefined antibody threshold as measured by the Pn ECL assay corresponding to the WHO enzyme-linked immunosorbent assay (ELISA) value of ≥ 1.0 μg/mL (post-dose 4) for the 13 serotypes in common with PREVNAR 13® (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and the 2 serotypes (serotypes 22F and 33F) not in common with PREVNAR 13®.</description>
          <population>The analysis population included all infant participants who did not have a protocol violation that could have impacted the validity of the antibody responses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="298"/>
                <count group_id="O3" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="72.1" upper_limit="82.3"/>
                    <measurement group_id="O2" value="76.5" lower_limit="71.3" upper_limit="81.2"/>
                    <measurement group_id="O3" value="84.1" lower_limit="79.3" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="296"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="57.6" upper_limit="69.3"/>
                    <measurement group_id="O2" value="56.8" lower_limit="50.9" upper_limit="62.5"/>
                    <measurement group_id="O3" value="30.9" lower_limit="25.5" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="56.0" upper_limit="67.8"/>
                    <measurement group_id="O2" value="65.1" lower_limit="59.4" upper_limit="70.5"/>
                    <measurement group_id="O3" value="73.3" lower_limit="67.7" upper_limit="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="74.4" upper_limit="84.2"/>
                    <measurement group_id="O2" value="75.8" lower_limit="70.6" upper_limit="80.6"/>
                    <measurement group_id="O3" value="85.1" lower_limit="80.4" upper_limit="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="297"/>
                    <count group_id="O3" value="279"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="85.6" upper_limit="93.1"/>
                    <measurement group_id="O2" value="89.2" lower_limit="85.1" upper_limit="92.5"/>
                    <measurement group_id="O3" value="97.5" lower_limit="94.9" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="94.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="92.6" lower_limit="89.0" upper_limit="95.3"/>
                    <measurement group_id="O3" value="95.4" lower_limit="92.2" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="93.4" upper_limit="98.2"/>
                    <measurement group_id="O2" value="97.0" lower_limit="94.3" upper_limit="98.6"/>
                    <measurement group_id="O3" value="99.3" lower_limit="97.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="84.3" upper_limit="92.2"/>
                    <measurement group_id="O2" value="87.9" lower_limit="83.7" upper_limit="91.4"/>
                    <measurement group_id="O3" value="91.5" lower_limit="87.6" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="92.1" upper_limit="97.5"/>
                    <measurement group_id="O2" value="97.0" lower_limit="94.3" upper_limit="98.6"/>
                    <measurement group_id="O3" value="98.2" lower_limit="95.9" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="78.7" upper_limit="87.8"/>
                    <measurement group_id="O2" value="74.5" lower_limit="69.2" upper_limit="79.3"/>
                    <measurement group_id="O3" value="95.0" lower_limit="91.8" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" lower_limit="83.2" upper_limit="91.3"/>
                    <measurement group_id="O2" value="87.9" lower_limit="83.7" upper_limit="91.4"/>
                    <measurement group_id="O3" value="96.4" lower_limit="93.6" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="92.1" upper_limit="97.5"/>
                    <measurement group_id="O2" value="97.0" lower_limit="94.3" upper_limit="98.6"/>
                    <measurement group_id="O3" value="95.7" lower_limit="92.7" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="272"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.0" upper_limit="100"/>
                    <measurement group_id="O2" value="98.7" lower_limit="96.6" upper_limit="100"/>
                    <measurement group_id="O3" value="2.8" lower_limit="1.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" lower_limit="70.9" upper_limit="81.3"/>
                    <measurement group_id="O2" value="70.5" lower_limit="64.9" upper_limit="75.6"/>
                    <measurement group_id="O3" value="86.4" lower_limit="81.9" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F (non-PREVNAR 13® serotype)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="298"/>
                    <count group_id="O3" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="92.9" upper_limit="98.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="93.9" upper_limit="98.4"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 1 month after final vaccination</time_frame>
      <desc>The safety population consisted of all randomized participants who received study vaccine.</desc>
      <group_list>
        <group group_id="E1">
          <title>V114</title>
          <description>Participants received four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
        <group group_id="E2">
          <title>V114 Non-Adjuvanted</title>
          <description>Participants received four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
        <group group_id="E3">
          <title>Prevnar</title>
          <description>Participants received four 0.5 mL IM doses of PREVNAR 13® at 2, 4, 6, and 12 to 15 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="368"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="368"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="382"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="345" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="348" subjects_at_risk="382"/>
                <counts group_id="E3" subjects_affected="347" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="368"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="382"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="36" subjects_at_risk="368"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="382"/>
                <counts group_id="E3" events="39" subjects_affected="36" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="368"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="382"/>
                <counts group_id="E3" events="27" subjects_affected="25" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="475" subjects_affected="217" subjects_at_risk="368"/>
                <counts group_id="E2" events="348" subjects_affected="179" subjects_at_risk="382"/>
                <counts group_id="E3" events="400" subjects_affected="201" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="314" subjects_affected="163" subjects_at_risk="368"/>
                <counts group_id="E2" events="180" subjects_affected="112" subjects_at_risk="382"/>
                <counts group_id="E3" events="324" subjects_affected="160" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="687" subjects_affected="264" subjects_at_risk="368"/>
                <counts group_id="E2" events="632" subjects_affected="280" subjects_at_risk="382"/>
                <counts group_id="E3" events="647" subjects_affected="271" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="378" subjects_affected="181" subjects_at_risk="368"/>
                <counts group_id="E2" events="235" subjects_affected="132" subjects_at_risk="382"/>
                <counts group_id="E3" events="332" subjects_affected="165" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1072" subjects_affected="315" subjects_at_risk="368"/>
                <counts group_id="E2" events="1005" subjects_affected="311" subjects_at_risk="382"/>
                <counts group_id="E3" events="988" subjects_affected="306" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="197" subjects_affected="123" subjects_at_risk="368"/>
                <counts group_id="E2" events="147" subjects_affected="86" subjects_at_risk="382"/>
                <counts group_id="E3" events="186" subjects_affected="110" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="368"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="382"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="368"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="382"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="368"/>
                <counts group_id="E2" events="44" subjects_affected="41" subjects_at_risk="382"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="492" subjects_affected="212" subjects_at_risk="368"/>
                <counts group_id="E2" events="405" subjects_affected="195" subjects_at_risk="382"/>
                <counts group_id="E3" events="397" subjects_affected="196" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="743" subjects_affected="263" subjects_at_risk="368"/>
                <counts group_id="E2" events="756" subjects_affected="281" subjects_at_risk="382"/>
                <counts group_id="E3" events="689" subjects_affected="265" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="368"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="382"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

